

## Disclosures

### Personal Commercial (15)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Abiomed	Other - <i>travel reimbursement for research meeting</i>	Significant ( $\geq$ \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Accelaron	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	<a href="#">Pulmonary Hypertension and Venous Thromboembolic</a>
Acorai	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Alleviant	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Aria CV	Stock	Modest ( $<$ \$5,000)	<a href="#">Pulmonary Hypertension and Venous Thromboembolic</a>
Cytokinetics	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Edwards LifeSciences	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Endotronix	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Gradient	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<a href="#">Pulmonary Hypertension and Venous Thromboembolic</a>
Medtronic	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Merck	Other - <i>Hemodynamic Core Lab; steering committee</i>	Significant ( $\geq$ \$5,000)	<a href="#">Pulmonary Hypertension and Venous Thromboembolic</a>
Morphic Therapeutics	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<a href="#">Pulmonary Hypertension and Venous Thromboembolic</a>
Restore Medical	Data Safety Monitoring Board	Modest ( $<$ \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
United Therapeutics	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<a href="#">Pulmonary Hypertension and Venous Thromboembolic</a>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Task Force Co-Chair for WSPH - PH due to left heart disease	Other	None (\$0)	<a href="#">Pulmonary Hypertension and Venous Thromboembolic</a>

### Clinical Trial Enroller (4)

Trial Name	Trial Sponsor	Trial Funding Source
ALIVE study	bioventrix	
SOCIAL-HF	National Institutes of Health	
VENUS HF	Precardia	
HELP study	Tenax	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (6)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				

Year	Case Title	Represented	Description	Compensation
2021	cardiorespiratory arrest	Defendant		Significant (>= \$5,000)
2020	hyperkalemia	Defendant		Significant (>= \$5,000)
2019	aortic stenosis	Defendant	Cases of critical AS	Significant (>= \$5,000)
2017	heart failure	Defendant		Significant (>= \$5,000)
2016	heart failure/SCD	Defendant	death from arrhythmia	Modest (< \$5,000)
2016	acute coronary syndrome	Plaintiff † Lawfirm	Sudden death	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 9/21/2023  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 9/21/2023  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

**Embargo** | Signed on 9/21/2023  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

**On-Going Obligation Agreement** | Signed on 3/30/2024

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.